Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension - Archive ouverte HAL Access content directly
Journal Articles FASEB Journal Year : 2018

Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension

(1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3) , (1, 2, 3)
1
2
3

Abstract

Heightened pulmonary artery smooth muscle cell (PA-SMC) proliferation and migration and dynamic remodeling of the extracellular matrix are hallmark pathogenic features of pulmonary arterial hypertension (PAH). Pirfenidone (PFD) is an orally bioavailable pyridone derivative with antifibrotic, antiinflammatory, and antioxidative properties currently used in the treatment of idiopathic pulmonary fibrosis. We therefore evaluated the efficacy of curative treatments with PFD in the sugen/hypoxia (SuHx) rat model of severe pulmonary hypertension. Treatment with PFD (30 mg/kg per day by mouth 3 times a day for 3 wk) started 5 wk after sugen injection partially reversed established pulmonary hypertension, reducing total pulmonary vascular resistance and remodeling. Consistent with these observations, we found that continued PFD treatment decreases PA-SMC proliferation and levels of extracellular matrix deposition in lungs and right ventricles in SuHx rats. Importantly, PFD attenuated the proproliferative and promigratory potentials of cultured PA-SMCs from patients with idiopathic PAH and their capacity to produce extracellular matrix components. Finally, we found that PFD dose dependently enhanced forkhead box O1 protein levels and its nuclear translocation in cultured idiopathic PAH PA-SMCs and in PFD-treated SuHx rats. PFD appears to be a potential therapy for PAH worthy of investigation and evaluation for clinical use in conjunction with current PAH treatments.-Poble, P.-B., Phan, C., Quatremare, T., Bordenave, J., Thuillet, R., Cumont, A., Huertas, A., Tu, L., Dorfmüller, P., Humbert, M., Ghigna, M.-R., Savale, L., Guignabert, C. Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension.
Fichier principal
Vignette du fichier
2018=MS PIRF HAL.pdf (8.64 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-02581079 , version 1 (19-05-2020)

Identifiers

Cite

Paul-Benoit Poble, Carole Phan, Timothée Quatremare, Jennifer Bordenave, Raphaël Thuillet, et al.. Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2018, 33 (3), pp.3670-3679. ⟨10.1096/fj.201801659R⟩. ⟨inserm-02581079⟩
140 View
125 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More